International Biosafety: A Global Imperative

An international biosafety protocol is being debated under the Congress of the Parties to the Convention on Biodiversity (COP) that emerged from the Earth Summit in Rio de Janeiro in 1992. This might seem superficially odd. What does biodiversity have to do with biosafety? Yet the convention provides a unique opportunity to try to prevent dangerous projects with recombinant DNA and related techniques-"biotechnology" as the term is popularly used. The journey of biosafety to the COP began beca

Written byPhilip Regal
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

The journey of biosafety to the COP began because biotech promoters convinced United Nations agencies and Third World countries that root economic problems that contribute to the loss of biodiversity can be solved by investing heavily in biotechnology. Biotech would also mine "genetic gold" from tropical biodiversity and thus provide a rationale for preserving biodiversity.

Biotech promoters managed to include in Chapter 16 of Agenda 21 (the Rio agenda for action) a $20 billion-per-year Third World investment in biotech to solve their problems and thus protect biodiversity.

Conservation organizations objected on the grounds that a crash program of investment in an expensive technology with a poor track record for living up to its assurances, even in technologically advanced countries, would be an enormous gamble. Failure of many projects is likely, and this would increase Third World debt and thus actually hasten the destruction of nature, because ob- ligations to service ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies